is a dreaded condition often associated with smoking. Non-Small Cell Lung Cancer (NSLC) is the most common type of lung cancer and is responsible for the most cancer deaths worldwide. It is difficult to diagnose it early leading to an overall five-year survival rate of just 14%. Based on the type of cells of the cancer, lung cancer can be classified as Small Cell Lung Cancer and Non-Small Cell Lung Cancer (NSCLC). NSCLC is further classified into adenocarcinoma, squamous cell carcinoma and large cell carcinoma.
A recent report by the Global Business Intelligence Research provides hope for the treatment of NSCLC. According to the report, there are several drugs that are in various stages of development for the treatment of NSCLC. These drugs act differently from traditional chemotherapy drugs and could possibly be more effective than some of the currently available medications.
Several of these drugs are the first of their type with a new and unique mechanism to treat NSCLC, and are referred to as first-in-class drugs.
These new drugs are likely to be effective against the cancer with lesser effects on the normal cells of the body, thereby resulting in lesser systemic adverse effects.
The advantage of having the drugs in various developmental stages is that they will be approved at different times, thus ensuring that new drugs are continuously available in the market.
Drugs Used to Treat NSCLC:
Chemotherapy drugs are currently used for the treatment of NSCLC.
In some cases, they are used after surgery. This type of therapy is called adjuvant therapy.
In some other cases, they are used before surgery to shrink the size of the tumor. This is referred to as neoadjuvant therapy.
Drugs commonly used in the treatment of NSCLC are:
- Cisplatin or carboplatin plus docetaxel
Newer targeted treatments that are already available for NSCLC are:
Prognosis of NSCLC depends on the stage of diagnosis and is usually poor. It is hoped that the newer drugs will help to deal with the cancer better and lead to better long-term survival rates.